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Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and 
kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of 
Vγ9Vδ2 T cells in vitro. However, this inclination is often lost in vivo due to multiple 
mechanisms mediated by tumor cells and local microenvironment. Multiple myeloma 
(MM) is a paradigm disease in which antitumor immunity is selectively impaired at 
the tumor site. By interrogating the immune reactivity of bone marrow (BM) Vγ9Vδ2 
T cells to phosphoantigens, we have revealed a very early and long-lasting impairment 
of Vγ9Vδ2 T-cell immune functions which is already detectable in monoclonal gam-
mopathy of undetermined significance (MGUS) and not fully reverted even in clinical 
remission after autologous stem cell transplantation. Multiple cell subsets [MM cells, 
myeloid-derived suppressor cells, regulatory T  cells, and BM-derived stromal cells 
(BMSC)] are involved in Vγ9Vδ2 T-cell inhibition via several immune suppressive mech-
anisms including the redundant expression of multiple immune checkpoints (ICPs). 
This review will address some aspects related to the dynamics of ICP expression in the 
BM of MM patients in relationship to the disease status (MGUS, diagnosis, remission, 
and relapse) and how this multifaceted ICP expression impairs Vγ9Vδ2 T-cell function. 
We will also provide some suggestions how to rescue Vγ9Vδ2 T cells from the immune 
suppression operated by ICP and to recover their antimyeloma immune effector func-
tions at the tumor site.
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inTRODUCTiOn
Vγ9Vδ2 T cells have gained a solid reputation in cancer immunotherapy for their capacity to 
bridge innate and adaptive immunity and to participate to a multifaceted array of direct and 
indirect antitumor immune responses (1). Hematological malignancies, and especially B-cell 
malignancies, are privileged targets of Vγ9Vδ2 T-cell recognition and killing (2). This intrinsic 
susceptibility is due to the enhanced cell surface expression of stress-induced self-ligands and to 
the intense production of phosphorylated metabolites generated by the mevalonate (Mev) path-
way. Isopentenyl pyrophosphate (IPP) is the prototypic Mev metabolite recognized by Vγ9Vδ2 
T cells via TCR in association with the isoform A1 of the butyrophilin-3 (BTN3A1) protein family 
(3, 4). IPP is structurally related to the phosphoantigens generated by bacteria and stressed cells 
that are patrolled by Vγ9Vδ2 T cells as part of their duty to act as first-line defenders against 
infections and stressed cell at risk of malignant transformation (5).
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One strategy commonly used in vivo and in vitro to activate 
Vγ9Vδ2 T  cells is the stimulation of tumor cells, monocytes, 
and dendritic cells (DC) with aminobisphosphonates (NBP) 
like pamidronate and zoledronate (ZA) (6). These drugs inhibit 
farnesylpyrophosphate synthase in the Mev pathway (7) leading 
to intracellular IPP accumulation and extracellular IPP release 
which is sensed by Vγ9Vδ2 T cells via TCR and BTN3A1 (8). 
Wilhelm and colleagues (9) were the first to demonstrate that 
activation of Vγ9Vδ2 T  cells with pamidronate and low-dose 
interleukin 2 (IL-2) could induce clinical responses in patients 
with B-cell lymphomas and multiple myeloma (MM). The ability 
of peripheral blood (PB) Vγ9Vδ2 T cells to proliferate in vitro 
after stimulation with pamidronate and IL-2 was a predictor 
of clinical response. A clinical trial of adoptively transferred 
ex vivo activated Vγ9Vδ2 T  cells in combination with ZA and 
IL-2 was well tolerated, but showed very limited clinical efficacy 
(9). Additional studies in solid tumors have also fallen short 
of clinical expectations (10–13). Understanding why Vγ9Vδ2 
T  cells perform so poorly when intentionally recruited in  vivo 
or ex vivo to kill tumor cells is mandatory to really exploit their 
antitumor properties. One possible explanation is that activated 
Vγ9Vδ2 T cells do not reach the tumor site or, if reached, they are 
overwhelmed by the immune suppressive contexture operated by 
tumor cells and neighboring cells in the tumor microenviron-
ment (TME).
The TME is the protective niche which helps tumor cell to 
resist chemotherapy and escape immune surveillance (14). 
Although immune effector cells are often recruited in the TME 
by the tumor mutational load and the inflammatory milieu, their 
antitumor functions are blunted by direct or indirect inhibitory 
signals generated by tumor cells and neighboring cells in the 
TME (15). Vγ9Vδ2 T cells are not exempted from this immune 
suppressive contexture operated via soluble and cellular factors 
(16). Soluble factors include transforming growth factor-β, 
prostaglandins, and kynurenins (17–19). Cellular factors include 
regulatory T  cells (Tregs), myeloid-derived suppressor cells 
(MDSC), bone marrow-derived stromal cells (BMSC), and others. 
The discovery that immune checkpoints (ICPs) and their ligands 
(ICP-L) are abundantly expressed by tumor cells, immune effec-
tor cells, and immune suppressive cells have helped to understand 
the mechanisms promoting the immune suppressive cross talk in 
the TME and provided new opportunities of interventions.
In this review, we will discuss how the ICP/ICP-L circuitry 
undermines Vγ9Vδ2 T-cell function and how Vγ9Vδ2 T cells are 
very early and sensitive detectors of the TME immune suppres-
sive contexture in MM patients. Lessons learned from Vγ9Vδ2 
T cells in MM can be instrumental to improve Vγ9Vδ2 T-cell-
based immunotherapy in cancer.
THe iMMUne SUPPReSSive TMe  
in MYeLOMA
Multiple myeloma is a prototypic disease where malignant mye-
loma cells actively remodel the bone marrow (BM) microenvi-
ronment to establish a protective niche to support their growth, 
immune evasion, and drug resistance. MM is invariably preceded 
by a precursor asymptomatic stage of monoclonal gammopathy 
of undetermined significance (MGUS) with an estimated risk 
of progression to symptomatic disease ranging from less than 
1% to more than 3% per year. This range depends on risk fac-
tors traditionally ascribed to intrinsic features of myeloma cells. 
Genomic alterations determining clonal advantage are already 
detectable in MGUS indicating that the probability of progression 
is also dependent on extrinsic factors such as the composition 
of the surrounding TME (20). TME in MGUS and MM consists 
of a non-cellular component, the extracellular matrix, and of a 
heterogeneous cellular compartment that includes hematopoietic 
and non-hematopoietic cells. Both the non-cellular and cellular 
components are edited by myeloma cells to elude immune sur-
veillance and insure their undisturbed survival and progressive 
expansion (14, 15, 21).
Immune escape in the BM of MGUS and MM patients is 
achieved by shifting the balance between immune effector and 
immune suppressor functions as in many other cancers. The 
immune suppressive mechanisms include the local recruitment 
and/or activation of immune suppressor cells like Tregs, MDSC, 
the protumoral polarization of tumor-associated macrophages 
and/or mesenchymal stem cells, and the differentiation and acti-
vation of Th17 cells (22). The wane of immune effector functions 
includes impaired phagocytosis, ineffective antigen presentation, 
and T-cell costimulation by DC, B-cell defects and humoral 
deficiencies, and NK and NKT cell dysfunctions (23). The pro-
tumoral immune shift in the TME is driven by soluble factors 
and cellular interactions, including the recently discovered ICP/
ICP-L circuitry.
For many years, the conventional wisdom has been that the 
immune balance is tipped in favor of myeloma cell control in 
MGUS and early stages of MM, whereas the balance is tipped in 
favor of myeloma cell growth in advanced disease. The wisdom 
was based on the results obtained from experiments exploring 
the phenotype and function of T cells, NK cells, and NKT cells 
in MGUS and early MM stages compared to advanced MM 
stages (24–26). Nowadays, it is clear that the TME of MGUS 
subjects already harbor a number of immune dysfunctions. The 
functional interrogation of pAg reactivity of Vγ9Vδ2 T cells in 
MGUS and MM patients at different stages of the disease (diag-
nosis, remission, and relapse) has been particularly enlightening 
(Figure 1). We have previously shown that Vγ9Vδ2 T cells from 
approximately 50% of MM patients are anergic to ZA stimulation 
at diagnosis when this assay is performed in PB and monocytes 
are used to generate IPP (27) (Figure 1B). The anergy is reversible 
if ZA-treated DC, and not monocytes, are used to stimulate PB 
Vγ9Vδ2 T cells, one possible explanation being that the higher 
IPP production by DC after ZA stimulation (28, 29). The propor-
tion of anergic MM patients increases to 80–90% if ZA stimula-
tion is carried out in the BM using monocytes as IPP-presenting 
cells. Unlike PB, the strategy to use ZA-treated DC to recover 
Vγ9Vδ2 T-cell proliferation in the BM is ineffective (Figure 1C), 
and neither the removal nor the functional inhibition of sup-
pressive cells like Tregs or MDSC are sufficient to recover BM 
Vγ9Vδ2 T-cell proliferation (30). Crossover experiments have 
clearly shown that the defective pAg reactivity is peculiar to BM 
Vγ9Vδ2 T cells, which do not proliferate no matter whether they 
FigURe 1 | Vγ9Vδ2 T-cell impairment in the immune suppressive TME of MM patients. The stimulation of monocytes or DC with zoledronate (ZA) and low dose of 
IL-2 is commonly used in vitro to induce IPP-dependent Vγ9Vδ2 T-cell activation. (A) This approach is uniformly effective in healthy donors (Ctrl), no matter whether 
Vγ9Vδ2 T cells are from the PB or the BM. ZA-treated DC are more effective than ZA-treated monocytes to induce Vγ9Vδ2 T-cell activation because they produce 
higher IPP amounts. (B) PB Vγ9Vδ2 T cells are refractory to ZA stimulation (gray colored) in about 50% of MM patients at diagnosis, when monocytes are used as 
stimulators. Anergy in these patients can be recovered if ZA-treated DC instead of monocytes are used as stimulators. (C) BM Vγ9Vδ2 T cells from MM patients  
are uniformly anergic to ZA stimulation and the anergy is not corrected by ZA-treated DC. (D) The immune suppressive TME of MGUS and MM patients includes 
suppressor cells like Tregs, MDSC, and BMSC (that produce high amounts of IPP). The proportion of these cells is very similar irrespective of the disease status. 
MDCS are PD-L1+ in MGUS and MM irrespective of the disease status and release high amounts of IPP in the TME. Other cells playing a major role in the TME are 
macrophages, endothelial cells, and osteoclasts. The proportion of these cells is variable according to diagnosis and disease status. The defective pAg reactivity of 
Vγ9Vδ2 T-cell (gray colored) is present in MGUS, MM at diagnosis, MM in remission, and MM in relapse. Elimination of myeloma cells (that are PD-L1+ and release 
IPP) is insufficient in the short/intermediate term to recover Vγ9Vδ2 T-cell functions. It is possible that the persistence of PD-L1+ cells in the TME (i.e., MDSC), high 
levels of extracellular IPP, and PD-1 expression (and other ICP) on their cell surface continue to render functionally incompetent BM Vγ9Vδ2 T cells even in the 
remission phase. Abbreviations: DC, dendritic cells; ZA, zoledronate; IPP, isopentenyl pyrophosphate; PB, peripheral blood; BM, bone marrow; Ctrl, healthy 
subjects; MM, multiple myeloma; Tregs, regulatory T cells; MDSC, myeloid-derived suppressor cells; BMSC, bone marrow-derived stromal cells; MGUS, monoclonal 
gammopathy of undetermined significance; TME, tumor microenvironment; ICP, immune checkpoint; PD-1, programmed cell death protein 1.
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are stimulated with BM- or PB-derived ZA-treated DC. Vγ9Vδ2 
T-cell anergy is already detectable in the BM of MGUS individu-
als, largely anticipating the dysfunction of T and NKT cells. BM 
Vγ9Vδ2 T cells remain anergic to pAg stimulation also in MM 
patients who are in remission after autologous stem cell trans-
plantation (30) (Figure 1D). Altogether, these data indicate that 
Vγ9Vδ2 T cells are unique among other immune effector cells in 
sensing the very early and persistent immune suppressive TME 
commitment in MGUS and MM.
PROgRAMMeD CeLL DeATH PROTein 1 
(PD-1)/PD-L1 neTwORK iMPAiRS vγ9vδ2 
T-CeLL ACTivATiOn in THe TMe
Immune checkpoints/ICP-L are expressed by a variety of immune 
cells to control the strength and duration of immune responses 
and maintain T-cell homeostasis and self-tolerance (31). Smartly, 
tumor cells have learned very quickly how to hijack the ICP/
ICP-L circuitry to withstand immune recognition and onslaught. 
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and PD-1 
are so far the ICP more often targeted for therapeutic purposes 
(32). PD-1 is expressed on the surface of dysfunctional T and 
B cells and inhibits T cell-mediated apoptosis after engagement 
by PD-L1 expressed by tumor cells (33–36). The devilish plot to 
protect tumor cells from immune recognition and killing begins 
in the tumor-draining lymph nodes where the PD-1/PD-L1 
axis interferes with antigen presentation to blunt the activation 
of tumor-specific immune responses (37, 38). The inhibition of 
adaptive immune responses in secondary lymphoid organs is 
strategically implemented in the TME by ICP/ICP-L-dependent 
blockade of antitumor responses mediated by innate immunity 
(i.e., NK  cells and Vγ9Vδ2 T  cells) (30, 39). Based on these 
premises, ICP blockade (mainly pursued using anti-CTLA4 
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and/or anti-PD-1/PD-L1 mAbs) has been granted FDA approval 
in solid tumors and Hodgkin lymphoma (40, 41).
In the context of MM, increasing evidences suggest that the 
PD-1/PD-L1 pathway plays an active role in the generation of 
the immunosuppressive TME (42, 43). Myeloma cells offer high 
levels of PD-L1 to PD-1-expressing T and NK cells in the TME 
(43–45), and in  vitro studies showed enhanced myeloma cell 
killing by T and NK  cells after PD-1 and/or PD-L1 blockade 
(46). In a mouse model, Hallett and colleagues demonstrated 
that PD-L1 expression in myeloma cells decreases cytotoxic 
function, cytokine production, and proliferation of PD-1+ T and 
NK cells leading to their functional exhaustion (47). Consistent 
with this observation, Paiva et al. reported a prolonged survival 
in disseminated myeloma-bearing mice after PD-1 blocking 
(42), corroborating the therapeutic exploration of PD-1 block-
ade in MM.
However, unsatisfactory results of single agent anti PD-1 mAb 
failed to meet the expectations in the clinical setting. Combination 
approaches with immunomodulatory drugs (lenalidomide or 
pomalidomide) and dexamethasone proved synergistic effects 
in phase I/II trials, nurturing hopes for therapeutic exploitation 
of PD-1 blockade in MM (48–50). Immunotherapy with daratu-
mumab is currently under investigation as an alternative partner 
to improve efficacy of PD-1 blockade in a multiphase randomized 
clinical trial (NCT03357952) recruiting relapsed refractory 
myeloma patients. Only a deeper understanding of molecular 
mechanisms triggered by PD-1/PD-L1 signaling pathway may 
lead to rationally identify targeted strategies to overcome resist-
ance to PD-1 blockade.
Although the function of PD-1 has been extensively studied 
in mouse and human conventional αβ T  cells (51–53), little is 
known about the role of PD-1/PD-L1 signaling in human Vγ9Vδ2 
T cells. Iwasaki et al. analyzed PD-1 expression in PB Vγ9Vδ2 
T cells after pAg stimulation in healthy donors and breast cancer 
patient (54). They found that PD-1+ Vγ9Vδ2 T  cells in breast 
cancer patients produced less IFNγ had lower cytotoxic activity 
and CD107 degranulation than PD-1− cells after challenging with 
PD-L1+ tumor target cells. Zumwalde et  al. (55) have stressed 
the different kinetics of PD-1 expression in normal Vγ9Vδ2 
T cells upon pAg stimulation compared with tumor-experienced 
Vγ9Vδ2 T cells. BM Vγ9Vδ2 T cells from myeloma patients rep-
resent a paradigmatic example of functionally impaired tumor-
experienced Vγ9Vδ2 T cells. PD-1 expression in Vγ9Vδ2 T cells 
from normal donors peaks approximately 3–4  days after pAg 
stimulation afterward PD-1 expression returns to baseline values 
(55). This is very different compared with myeloma patients in 
which PD-1 expression increased in BM anergic Vγ9Vδ2 T cells 
after ZA stimulation, suggesting that these cells are intrinsi-
cally programmed to increase their threshold of refractoriness 
to pAg-induced TCR stimulation via PD-1 upregulation (30). 
Interestingly, PD-1 expression in myeloma BM Vγ9Vδ2 T cells 
is predominant in the central memory subset, which in normal 
conditions is the subset with the highest proliferative capacity to 
pAg stimulation (30).
One possible mechanism to explain PD-1 expression in BM 
Vγ9Vδ2 T cells, already detectable in MGUS when the myeloma 
cell infiltration is still low (<10% by definition), is the prolonged 
TCR engagement by pAg in the TME. Preliminary results from 
our lab indicate that myeloma cells are not the only IPP produc-
ers in the TME, and that BMSC in MGUS and MM also pro-
duce and release very high amounts of IPP in the extracellular 
microenvironment (8) (Figure  1D). Thus, it is possible that a 
chronic TCR engagement within an immune suppressive TME, 
characterized by inappropriate costimulatory signals and/or 
cytokines, leads to PD-1 expression and functional exhaustion 
of Vγ9Vδ2 T cells.
Our study has been the first to show that human MDSC 
are PD-L1+ in the TME suggesting that this is an additional 
mechanism exploited by these cells to exert local immune 
suppression against PD-1+ effector cells. Interestingly, the 
BM is highly hypoxic in MM (56) and experimental data in 
tumor-bearing mice have shown that the hypoxia-inducible 
factor-1α selectively upregulates PD-L1 in tumor-infiltrating 
MDSC, but not in MDSC from peripheral lymphoid organs 
(57). Hypoxia has been reported to increase the immune sup-
pressive TME contexture via upregulation of a variety of ICP/
ICP-L (58). Extracellular adenosine, which accumulates due 
to tissue hypoxia, also contributes to ICP/ICP-L upregulation 
(59), and adenosine levels are significantly higher in the BM 
of myeloma due to the highly coordinated expression of aden-
osinergic ecto-nucleotidases (CD39/CD73/CD38/CD203a) 
strategically located at the interface between myeloma cells 
and neighboring cells (60). Preliminary data from our lab 
indicate that BMSC, another major protumoral component in 
the BM niche of MGUS and MM patients, are PD-L1+, further 
confirming that there is a redundancy of immune suppressor 
cells exploiting the ICP/ICP-L circuitry to hamper myeloma 
cell recognition and elimination by immune effector cells in 
the TME. The finding that BM Vγ9Vδ2 T  cells are PD-1+ in 
MGUS, MM at diagnosis, and even in remission, confirms 
the unique sensitivity of these cells to the immune suppressor 
imprinting operated by the TME which is not overcome even 
when myeloma cells have been cleared from the BM. One pos-
sible explanation is that the immune suppression is exerted by 
PD-L1+ cells other than myeloma cells, like MDSC and BMSC, 
whose percentages and PD-L1 expression remain unchanged 
in the BM of MM in remission (30) (Figure 1D).
STRATegieS TO ReSCUe AnTiTUMOR 
vγ9vδ2 T-CeLL FUnCTiOn in THe TMe: 
LeSSOnS FROM MM
Clinical trials using anti-PD-1 mAbs as single agents in MM have 
failed to confirm the excellent premises of experimental data (61, 62). 
Interestingly, we have shown that single agent PD-1 blockade is 
insufficient to fully recover the antitumor activity of BM Vγ9Vδ2 
T cells in MM (30). Thus, Vγ9Vδ2 T cells are excellent tools to 
decipher the mechanisms developed by Vγ9Vδ2 T cells and other 
immune effector cells to resist immune recovery triggered by 
ICP/ICP-L blockade in the TME (Figure 2). Understanding these 
mechanisms of resistance is important to improve the efficacy of 
immune interventions based on ICP/ICP-L blockade in MM and 
other cancers.
FigURe 2 | Hypothetical mechanisms of resistance to PD-1 blockade in BM Vγ9Vδ2 T cells from MM patients. Left panel: BM Vγ9Vδ2 T cells in MGUS and MM  
are anergic to ZA + IL-2 stimulation; this anergy is only partially rescued by single agent PD-1 blockade. Right panel: possible mechanisms of resistance to immune 
recovery triggered by single agent PD-1 blockade. (A) Alternative inhibitory ICPs, such as TIM-3, TIGIT, and LAG-3, are expressed by BM Vγ9Vδ2 T cells to reinforce 
their anergy and resist to PD-1 blockade; (B) Vγ9Vδ2 T cells have been functionally polarized to express inhibitory molecules (FOXP3, CD73, CD39, and CD38)  
and release immune suppressive cytokines (IL-10) as a consequence of their long-term exposure to tumor cells in the BM; (C) BM Vγ9Vδ2 T cells have acquired a 
senescence status (CD57+CD160+KLRG-1+CD28− phenotype) which is hard to reverse by single PD-1 blockade; (D) PD-1 engagement of anergic/senescent BM 
Vγ9Vδ2 T cells induces the expression of PD-L1 and galectin-9 (GAL-9), and IL-17 secretion leading to immune suppressive effects on other effector cells like CD8+ 
cells. Abbreviations: MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; BM, bone marrow; TME, tumor microenvironment; ZA, 
zoledronate; IL-2, interleukin 2; ICP, immune checkpoint; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; LAG-3, lymphocyte-activation gene 3; 
PD-1, programmed cell death protein 1.
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One mechanism could be the expression of alternative ICP 
under resting conditions or after pAg stimulation and/or PD-1 
blockade (Figure 2, option A). Double PD-1 and T-cell immuno-
globulin and mucin-domain containing-3 (TIM-3) expression in 
tumor-infiltrating lymphocytes from tumor-bearing mice identi-
fies the most dysfunctional CD8+ T  cells in the TME of these 
mice, and concurrent PD-1 and TIM-3 blockade significantly 
improves the antitumor activity of these cells, much better than 
single inhibition (63). The expression of multiple ICP/ICP-L 
expression on individual immune cells and tumor cells has 
recently been proposed as a mechanism of acquired resistance 
to single PD-1 blockade also in human cancer (64, 65). TIM-3, 
lymphocyte-activation gene 3 (LAG-3), and TIGIT are examples 
of alternative ICP that could be expressed on the cell surface of 
BM Vγ9Vδ2 T cells and could restrain the efficacy of single PD-1 
blockade. Targeting multiple ICP could be an attractive strategy 
to improve the recovery of antitumor Vγ9Vδ2 T-cell responses 
(Figure 2, option A).
Another mechanism could be the regulatory/suppressor 
polarization of BM Vγ9Vδ2 T cells driven by the TME (66, 67). 
This functional polarization cannot be reverted by single PD-1 
blockade. Vγ9Vδ2 T cells with regulatory functions have initially 
been described by Casetti et al. (68), who reported the in vitro 
induction of FOXP3+ regulatory Vγ9Vδ2 T  cells after pAg 
stimulation in the presence of TGF-β1 and IL-15. Other groups 
have confirmed the emergence of regulatory/suppressor Vγ9Vδ2 
T  cells as a consequence of pAg activation in the presence of 
selected cytokines (69, 70). Ma et al. have reported an increased 
proportion of regulatory Vγ9Vδ2 T cells in the PB of MM patients 
which could suppress antimyeloma immune responses with the 
same efficiency of conventional Tregs (71).
Single PD-1 blockade may not be sufficient to revert the regula-
tory/suppressor polarization of BM Vγ9Vδ2 T cells. Preliminary 
data in our lab indicate that PD-1 blockade of BM Vγ9Vδ2 
T cells in MM could even worsen this polarization by inducing 
the expression of additional inhibitory molecules (FOXP3, CD73, 
CD39, and CD38) and the release of suppressive factors like 
IL-10 (Figure 2, option B). In this case, PD-1 blockade should 
be integrated by strategies aimed at preventing the detrimental 
BM Vγ9Vδ2 T-cell polarization and/or the regulatory/suppressor 
functions exerted by polarized Vγ9Vδ2 T cells in the TME.
Another major hurdle preventing the full recovery of anti-
tumor Vγ9Vδ2 T-cell functions by PD-1 blockade could be their 
immune senescence status (Figure 2, option C). Immune senes-
cence is the hallmark of oligoclonal T cells which accumulate in 
the PB of MM patients with progressive and advanced disease 
(72–74). The immune competence of senescent cells is very hard 
to resurrect by single PD-1 blockade. The CD57+CD160+KLRG-
1+CD28− phenotype might portray a distinct population of 
senescent Vγ9Vδ2 T cells gathered in the BM of MM patients 
which require multiple approaches to overcome resistance to 
PD-1 blockade.
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Finally, the acquisition of protumoral functions by Vγ9Vδ2 
T cells that are long-term resident in the TME could be another 
mechanism of resistance to single PD-1 blockade. The inappro-
priate expression of ICP-L such as PD-L1 and galectin-9 (GAL-9) 
in Vγ9Vδ2 T cells could affect via PD-1 and TIM-3 the antitumor 
responses of other immune effector cells in the TME (Figure 2, 
option D). Likewise, production of IL-17 by Vγ9Vδ2 T  cells, 
as reported for selected γδ subsets in solid tumors (75), may 
contribute to reinforce the immune suppressive TME imprinting 
by recruiting MDSC (76) and polarizing neutrophils (77). This 
hypothetical scenario suggests that PD-L1/GAL-9 and IL-17 
(or its receptor) could be novel targets to rescue antimyeloma 
Vγ9Vδ2 T-cell function.
Whether the mechanisms reported above are operative under 
baseline conditions or sharpened by pAg stimulation in the pres-
ence of PD-1 blockade is a matter of current investigation in our 
lab. Preliminary data suggest that the intracellular metabolic and 
signaling pathways evoked by PD-1 blockade could worsen the 
immune competence status of pAg-experienced Vγ9Vδ2 T cells.
COnCLUSiOn
Vγ9Vδ2 T cells are programmed by default to behave as very effec-
tive professional killers of malignant B cells, including myeloma 
cells. We propose that Vγ9Vδ2 T cells are very precociously neu-
tralized by myeloma cells in cooperation with neighboring cells 
in the TME of MGUS and MM patients. Finalistically speaking, 
it makes sense that myeloma cells inactivate or co-opt in their 
favor those immune cells mostly well suited to threaten their 
survival. This is done very early at the stage of MGUS and the 
uncontrolled production of IPP by BMSC and myeloma cells is 
probably a relevant initiating event.
Functional interrogation of BM Vγ9Vδ2 T  cells from MM 
patients in remission has revealed that clearance of myeloma 
cells does not automatically imply the recovery of a fully immune 
competent TME.
ICP/ICP-L abundantly expressed by tumor cells, immune 
effector cells, and immune suppressive cells are major promot-
ers of immune suppressive cross talks in the TME at any stage 
and hamper the antimyeloma activity of BM Vγ9Vδ2 T  cells. 
Single agent PD-1 blockade is insufficient to fully recover 
the antitumor activity of Vγ9Vδ2 T  cells in  vitro, especially 
in MM at diagnosis or in relapse. These data indicate that 
additional immune suppressive mechanisms are involved in 
the anergy of Vγ9Vδ2 T  cells. A working knowledge of these 
mechanisms may yield insight into the development of more 
effective interventions to fully exploit the immune potency 
of Vγ9Vδ2 T  cells in MM and other cancers. This knowledge 
could be profitably implemented by next generation sequencing 
studies investigating the genetic and epigenetic consequences 
of cell-to-cell interactions of Vγ9Vδ2 T  cells and other cell 
subsets in the TME of MGUS and MM patients.
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